Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
Bulios Fair Price
$7.42
34.5% downside
Current Price
$11.34
According to Bulios Fair Price, DNA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Ginkgo Bioworks Holdings, Inc. (DNA) is a biotechnology company focused on synthetic biology and engineering microorganisms. The company uses advanced technologies and biological systems to create new organisms and biological functions for various applications. Ginkgo Bioworks specializes in genetic modification and design of microorganisms, enabling the production of novel drugs, biochemical substances, industrial products, and other biologically-based technologies. The company collaborates with various industries and pharmaceutical companies on the development of new products and innovations that can have a positive impact on the environment and human health. Ginkgo Bioworks Holdings, Inc. (DNA) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focused on innovation and the development of biological technologies with the potential for broader societal impact.
Sector
Healthcare
Industry
Biotechnology
CEO
Jason Kelly
Employees
485
Headquarters
Boston
Upcoming events
Earnings
Upcoming earnings report